Article Text

PDF
Letter
Liver resection for patients with hepatocellular carcinoma and macrovascular invasion, multiple tumours, or portal hypertension
  1. Jian-Hong Zhong1,
  2. Yang Ke1,2,
  3. Yan-Yan Wang1,
  4. Le-Qun Li1
  1. 1 Hepatobiliary Surgery Department, Affiliated Tumor Hospital of Guangxi Medical University, Nanning, PR China
  2. 2 Hepatobiliary Surgery Department, The Second Affiliated Hospital of Kunming Medical University, Kunming, PR China
  1. Correspondence to Dr Jian-Hong Zhong and Dr Le-Qun Li, Hepatobiliary Surgery Department, Affiliated Tumor Hospital of Guangxi Medical University, He Di Rd. #71, Nanning 530021, P.R. China; zhongjianhong66{at}163.com; xitongpingjia{at}163.com

Statistics from Altmetric.com

Sir,

We read with great interest the leading article by Bruix et al 1 published in Gut. This article recommended palliative treatments for patients with hepatocellular carcinoma (HCC) involving macrovascular invasion, multiple tumours, or portal hypertension.

With better patient selection and improvement of perioperative care, liver resection (LR) offers the most consistent and clinically meaningful long-term survival in HCC over the past 20 years, which has been documented by both Eastern and Western centres.2 ,3 However, Western official guidelines do not recommend LR for treating intermediate and advanced stage HCC.4 ,5 Here, we systematically searched PubMed database for studies investigating the safety and efficacy of LR for treating patients with HCC involving macrovascular invasion, multiple tumours (≥2) or portal hypertension. We only included studies which were published in English on …

View Full Text

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Linked Articles